↓ Skip to main content

Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer

Overview of attention for article published in BMC Clinical Pathology, December 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
38 Dimensions

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer
Published in
BMC Clinical Pathology, December 2017
DOI 10.1186/s12907-017-0067-7
Pubmed ID
Authors

Ayşe Latif, Amy L. Chadwick, Sarah J. Kitson, Hannah J. Gregson, Vanitha N. Sivalingam, James Bolton, Rhona J. McVey, Stephen A. Roberts, Kay M. Marshall, Kaye J. Williams, Ian J. Stratford, Emma J. Crosbie

Abstract

Endometrial cancer (EC) is a major health concern due to its rising incidence. Whilst early stage disease is generally cured by surgery, advanced EC has a poor prognosis with limited treatment options. Altered energy metabolism is a hallmark of malignancy. Cancer cells drive tumour growth through aerobic glycolysis and must export lactate to maintain intracellular pH. The aim of this study was to evaluate the expression of the lactate/proton monocarboxylate transporters MCT1 and MCT4 and their chaperone CD147 in EC, with the ultimate aim of directing future drug development. MCT1, MCT4 and CD147 expression was examined using immunohistochemical analysis in 90 endometrial tumours and correlated with clinico-pathological characteristics and survival outcomes. MCT1 and MCT4 expression was observed in the cytoplasm, the plasma membrane or both locations. CD147 was detected in the plasma membrane and associated with MCT1 (p = 0.003) but not with MCT4 (p = 0.207) expression. High MCT1 expression was associated with reduced overall survival (p = 0.029) and remained statistically significant after adjustment for survival covariates (p = 0.017). Our data suggest that MCT1 expression is an important marker of poor prognosis in EC. MCT1 inhibition may have potential as a treatment for advanced or recurrent EC.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 24%
Researcher 6 18%
Student > Master 5 15%
Lecturer 1 3%
Student > Doctoral Student 1 3%
Other 4 12%
Unknown 9 26%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 21%
Pharmacology, Toxicology and Pharmaceutical Science 5 15%
Medicine and Dentistry 4 12%
Chemistry 3 9%
Immunology and Microbiology 2 6%
Other 5 15%
Unknown 8 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2018.
All research outputs
#18,581,651
of 23,015,156 outputs
Outputs from BMC Clinical Pathology
#78
of 117 outputs
Outputs of similar age
#330,004
of 441,976 outputs
Outputs of similar age from BMC Clinical Pathology
#2
of 3 outputs
Altmetric has tracked 23,015,156 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 117 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,976 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.